PriceTargets.com logo

NuCana - NCNA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 1,983.33%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.20 As of 12/26/2024 11:05 AM ET
▼ -0.005 (-0.41%)

This chart shows the closing price for NCNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NuCana Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NCNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NCNA

Analyst Price Target is $25.00
▲ +1,983.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for NuCana in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 1,983.33% upside from the last price of $1.20.

This chart shows the closing price for NCNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in NuCana. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/3/2024OppenheimerLower TargetOutperform ➝ Outperform$150.00 ➝ $25.00
8/30/2024William BlairDowngradeOutperform ➝ Market Perform
8/19/2024OppenheimerReiterated RatingOutperform ➝ Outperform$150.00 ➝ $150.00
7/22/2024OppenheimerBoost TargetOutperform ➝ Outperform$4.00 ➝ $150.00
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$100.00
11/21/2023OppenheimerReiterated RatingOutperform ➝ Outperform$100.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$150.00
8/18/2023OppenheimerReiterated RatingOutperform ➝ Outperform$100.00
11/28/2022CitigroupLower Target$125.00 ➝ $50.00
9/22/2022Jefferies Financial GroupLower TargetBuy$525.00 ➝ $75.00
4/13/2022Truist FinancialLower Target$550.00 ➝ $150.00
3/3/2022CowenDowngradeOutperform ➝ Market Perform
11/24/2021HC WainwrightLower TargetBuy$250.00 ➝ $225.00
3/30/2021William BlairReiterated RatingBuy
1/19/2021HC WainwrightReiterated RatingBuy$250.00
12/1/2020HC WainwrightLower TargetBuy$375.00 ➝ $250.00
11/24/2020HC WainwrightLower TargetBuy$425.00 ➝ $375.00
10/22/2020Truist FinancialInitiated CoverageBuy$550.00
9/21/2020OppenheimerReiterated RatingBuy$525.00
8/21/2020Piper SandlerBoost TargetOverweight$375.00 ➝ $425.00
8/21/2020HC WainwrightBoost TargetBuy$400.00 ➝ $425.00
8/21/2020OppenheimerReiterated RatingBuy$525.00
7/29/2020CowenReiterated RatingMarket Perform ➝ Average
7/29/2020Piper SandlerReiterated RatingOverweight$375.00
7/23/2020OppenheimerInitiated CoverageOutperform$500.00
5/19/2020HC WainwrightReiterated RatingBuy$400.00
5/6/2020HC WainwrightReiterated RatingBuy
3/11/2020HC WainwrightLower TargetBuy$425.00 ➝ $400.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

-0.59 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
9/27/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NuCana logo
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More

Today's Range

Now: $1.20
Low: $1.20
High: $1.23

50 Day Range

MA: $1.45
Low: $1.21
High: $1.95

52 Week Range

Now: $1.20
Low: $1.17
High: $19.41

Volume

14,505 shs

Average Volume

413,025 shs

Market Capitalization

$3.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of NuCana?

The following sell-side analysts have issued reports on NuCana in the last year: Oppenheimer Holdings Inc., and William Blair.
View the latest analyst ratings for NCNA.

What is the current price target for NuCana?

0 Wall Street analysts have set twelve-month price targets for NuCana in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 1,983.3%. Oppenheimer Holdings Inc. has the highest price target set, predicting NCNA will reach $25.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $25.00 for NuCana in the next year.
View the latest price targets for NCNA.

What is the current consensus analyst rating for NuCana?

NuCana currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NCNA.

What other companies compete with NuCana?

Other companies that are similar to NuCana include TherapeuticsMD, Aspira Women's Health, ANEW Medical, Sol-Gel Technologies and Bright Green. Learn More about companies similar to NuCana.

How do I contact NuCana's investor relations team?

NuCana's physical mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company's listed phone number is 441313571111 and its investor relations email address is [email protected]. The official website for NuCana is www.nucana.com. Learn More about contacing NuCana investor relations.